[
    {
        "role": "user",
        "content": "I%20take%20ozempic%20enjection%20which%20cost%20158%20euro%20a%20month%20in%20dublin%20some%20time%20I%20am%20hoping%20it%20will%20be%20free%20or%20reduced%20in%20the%20long%20term%20illness%20for%20all%20conditions%20not%20just%20diabetic%20any%20ideas%3F"
    },
    {
        "role": "assistant",
        "content": "Here\u2019s a breakdown of what the current rules are in Ireland regarding Ozempic (semaglutide), who can get it either **free** or **subsidised**, and what might need to change if you're hoping for it to be available more broadly in the long term \u2014 especially for people without diabetes.\n\n---\n\n## What are the current rules?\n\n1. **What is Ozempic officially approved for**  \n   Ozempic is licensed in Ireland only for *type 2 diabetes*. ([doconcall.ie](https://doconcall.ie/ozempic-wegovy-mounjaro-ireland-guide/?utm_source=openai))\n\n2. **Cover under state schemes**  \n   - If you have **type 2 diabetes** and are registered under the **Long-Term Illness (LTI) Scheme** or have a **Medical Card**, you can get Ozempic free of charge. ([helloregimen.com](https://helloregimen.com/ie/blog/glp1-ireland-guide-2026?utm_source=openai))  \n   - Also, there\u2019s the **Drug Payment Scheme (DPS)** which caps monthly medicine costs at about **\u20ac80 per family/household**. Ozempic for diabetes can count under that. ([doxoncall.ie](https://doxoncall.ie/ozempic-wegovy-mounjaro-ireland-guide/?utm_source=openai))  \n\n3. **Dosage limits**  \n   The state reimbursement covers the **0.25 mg, 0.5 mg, and 1 mg weekly pens** under these schemes. The stronger 2 mg pen *isn\u2019t* currently reimbursed, because the manufacturer hasn\u2019t applied for its reimbursement under the relevant scheme. ([hse.ie](https://www.hse.ie/eng/about/personalpq/pq/2025-pq-responses/july-2025/pq-37990-25-padraig-o-sullivan.pdf?utm_source=openai))\n\n4. **For weight loss or other non-diabetic use**  \n   - If you\u2019re not diabetic and want Ozempic for obesity or weight management, it falls outside the approved indication. It is *not reimbursed* under LTI, Medical Card, DPS, or other HSE schemes. Wegovy (semaglutide 2.4 mg), licensed for obesity, is also not yet reimbursed. ([assets.hse.ie](https://assets.hse.ie/media/documents/Managed_Access_Protocol_-_Liraglutide_Saxenda_for_weight_management_in_adults.pdf?utm_source=openai))  \n   - The HSE explicitly restricts reimbursement to medicines for their approved indications. Off-licence prescribing (e.g. diabetes drugs for weight loss) is allowed clinically but *not funded*. ([hse.ie](https://www.hse.ie/eng/about/personalpq/pq/2025-pq-responses/april-2025/pq-16664-25-sean-canney.pdf?utm_source=openai))\n\n---\n\n## Why it's not available free/reduced for all conditions\n\nHere are the key barriers:\n\n- **Regulatory approval**: The government and HSE reimbursement bodies only fund medications for their official, Health Products Regulatory Authority-approved uses in Ireland. If Ozempic is prescribed off-label (e.g. for weight loss), then it\u2019s not covered. ([hse.ie](https://www.hse.ie/eng/about/personalpq/pq/2025-pq-responses/april-2025/pq-16664-25-sean-canney.pdf?utm_source=openai))  \n\n- **Pricing/reimbursement applications**: The manufacturer (Novo Nordisk) needs to apply for each indication and dosage strength to be added to the reimbursement list, via agencies like PCRS and NCPE. For example, the 2 mg pen hasn\u2019t been approved yet for reimbursement. ([hse.ie](https://www.hse.ie/eng/about/personalpq/pq/2025-pq-responses/july-2025/pq-37990-25-padraig-o-sullivan.pdf?utm_source=openai))\n\n- **Cost-effectiveness assessments**: For obesity indications or non-diabetes uses, the HSE and its pharmacoeconomics body need evidence that the benefit justifies the cost. For many treatments, these assessments are still underway or not yet made. ([hse.ie](https://www.hse.ie/eng/about/personalpq/pq/2025-pq-responses/may-2025/pq-28848-25-conor-sheehan.pdf?utm_source=openai))\n\n---\n\n## Potential paths to broader access\n\nIf you're hoping Ozempic could be free or subsidised beyond just type 2 diabetes, here are what likely need to happen:\n\n- **New licensing or formal recognition**: The active ingredient (semaglutide) is already licensed for obesity under **Wegovy**, but as of now, HSE hasn\u2019t approved that use or begun reimbursing for Wegovy. Ozempic as a brand for obesity is technically off-licence. ([doconcall.ie](https://doconcall.ie/ozempic-wegovy-mounjaro-ireland-guide/?utm_source=openai))\n\n- **Manufacturer submits pricing/reimbursement application** for the off-label or new indication use (e.g. obesity) and dosage forms (e.g. 2 mg pens) to PCRS/NCPE.\n\n- **Public health policy shift**: For example, obesity might be treated more like a chronic disease, which could lead to broader coverage in the same way that diabetes is. But that requires governmental decisions, budgeting, and health-economics justification.\n\n- **Advocacy and evidence**: More data on outcomes, cost savings, etc. (e.g. reduced complications, hospitalisations) can help make the case stronger.\n\n- **You may also qualify via medical card schemes** or other supports if your condition meets criteria. Checking with your GP or pharmacist to see whether any off-label uses have special pathways is worthwhile.\n\n---\n\n## What you can do personally\n\n- Ask your **GP** whether Ozempic for your condition might ever be approved under subsidy or if there are clinical trials/pilot programmes.\n\n- If you're paying privately, keep all invoices related to medical costs \u2014 you might be able to claim **tax relief** on them in Ireland as \u201cnon-reimbursed medical expenses.\u201d ([reddit.com](https://www.reddit.com/r/mounjaroIreland/comments/1q6d5pf/mounjaro_tirzepatide_users_in_ireland_you_can/?utm_source=openai))\n\n- Explore medical card eligibility, especially if your overall health/financial situation qualifies you.\n\n---\n\nIf you like, I can look up what the NCPE is currently reviewing, or whether there's a date projected for Wegovy reimbursement \u2014 that might give you a sense of when changes could realistically happen. Do you want me to do that?"
    }
]